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Introduction
Schizophrenia is a serious psychiatric condition with a lifetime 
prevalence of approximately 1%.1 Although its etiology is still 
largely unknown, schizophrenia is thought to result from a 
complex interplay of a subset of genetic and environmental 
factors.2,3 Despite its high genetic component — estimated to 
be approximately 80%1 — the identification and replication of 
genetic susceptibility factors for schizophrenia have proven 
challenging owing to the genetic and phenotypic heterogen­
eity that characterizes this disorder.1,2
In addition to multiple protein­coding genes that are im­
plicated in schizophrenia pathophysiology, recent evidence 
indicates that dysregulation of small, noncoding RNAs, such 
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Background: Schizophrenia is a highly heritable neurodevelopmental disorder. A genetic variant of microRNA-137 (miR-137) has yielded sig-
nificant genome-wide association with schizophrenia, suggesting that this miRNA plays a key role in its etiology. Therefore, a molecular net-
work of interacting miR-137 targets may provide insights into the biological processes underlying schizophrenia. Methods: We first used 
bioinformatics tools to obtain and analyze predicted human and mouse miR-137 targets. We then determined miR-137 levels in rat barrel cortex 
after environmental enrichment (EE), a neuronal plasticity model that induces upregulation of several predicted miR-137 targets. Subsequently, 
expression changes of these predicted targets were examined through loss of miR-137 function experiments in rat cortical neurons. Finally, we 
conducted bioinformatics and literature analyses to examine the targets that were upregulated upon miR-137 downregulation. Results: Pre-
dicted human and mouse miR-137 targets were enriched in neuronal processes, such as axon guidance, neuritogenesis and neurotransmis-
sion. The miR-137 levels were significantly downregulated after EE, and we identified 5 novel miR-137 targets through loss of miR-137 function 
experiments. These targets fit into a glucocorticoid receptor–dependent signalling network that also includes 3 known miR-137 targets with 
genome-wide significant association with schizophrenia. Limitations: The bioinformatics analyses involved predicted human and mouse miR-
137 targets owing to lack of information on predicted rat miR-137 targets, whereas follow-up experiments were performed with rats. Further-
more, indirect effects in the loss of miR-137 function experiments cannot be excluded. Conclusion: We have identified a miR-137-regulated 
protein network that contributes to our understanding of the molecular basis of schizophrenia and provides clues for future research into psycho-
pharmacological treatments for schizophrenia.
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as microRNAs (miRNAs), may play an important role in the 
etiology of the disorder.4 MicroRNA­encoding genes are 
highly conserved across evolution and have been shown to 
be involved in various fundamental biological processes.5 
They regu late the expression of target messenger RNAs 
(mRNAs) by binding to their 3′­untranslated region (UTR), 
causing  either mRNA degradation or protein synthesis 
inhibition.6,7 Each miRNA affects many mRNAs, while indi­
vidual mRNAs can be targeted by several miRNAs. Some 
miRNAs are highly enriched in the brain or are even brain­
specific, suggesting their unique regulatory roles in neuronal 
function,8 including the modulation of neuronal and synap­
tic plasticity9,10 and neuronal circuitry.11,12 In support of this 
notion, the miRNA target site density in synaptic mRNAs is 
twice as high as in nonsynaptic mRNAs.13 Furthermore, 
there have been numerous  studies implicating brain­ 
enriched miRNAs in the etiology of schizophrenia. For ex­
ample, a subset of brain­enriched miRNA genes located 
within an imprinted cluster on chromosomal region 14q32 
was differentially expressed in a large cohort of patients 
with schizophrenia.14 In addition, a microdeletion of chro­
mosomal region 22q11.2, harboring the brain­enriched miR­
185, has been consistently linked to schizophrenia, and dele­
tion of the corresponding region in the mouse resulted in an 
altered development of neuronal dendrites and spines.15 The 
most robust genetic evidence for the involvement of a 
miRNA in schizophrenia has emerged from a genome­wide 
association study (GWAS) with a sample of approximately 
50 000.16 In this study, a single­nucleotide polymorphism 
(SNP; rs1625579) located within an intron of the miR­137 
host gene (MIR137HG) achieved genome­wide sig nificance 
for association with schizophrenia.
Notably, rs1625579 (and hence miR­137) has also been 
gen etically associated with a number of schizophrenia 
endo phenotypes, including cognitive deficits, negative 
symptoms,17 brain activation,18,19 brain structure and age 
at disease onset.20 Moreover, apart from having a strong 
genetic link with schizophrenia, miR­137 is highly abun­
dant in hippocampal and cortical neurons, where it regu­
lates neuronal maturation and dendritic spine morpho­
genesis , 21 and more specifically in the synaptic 
compartment.22 In addition, miR­137 modulates the prolif­
eration and differentiation of murine adult neural stem 
cells,23 and its overexpression results in decreased den­
dritic spine size.21 Since disturbances in synaptic function 
and plasticity as well as in neuronal circuitry have also 
been associated with the onset and progression of schizo­
phrenia,13,24,25 we hypothesized that miR­137 is involved in 
modulating gene expression during synaptic plasticity 
and that miR­137­mediated regulation of plasticity­related 
genes is disturbed in patients with schizophrenia. There­
fore, we conducted bioinformatics and literature analyses 
to generate a molecular network of interacting miR­137 
targets. In addition, transcriptomics data were derived 
from a rat neuronal plasti city model of somatosensory ex­
perience, and loss of miR­137 function experiments in pri­
mary cortical neurons were performed to validate these 
interacting miR­137 targets.
Methods
All experimental protocols and procedures were approved by 
the Animal Ethics Committee of the Radboud University Nij­
megen (the Netherlands) and were in accordance with the Dutch 
legislation. Supplementary descriptions of the procedures we 
used are provided in the Appendix (available at jpn.ca).
Human and mouse miR-137 target prediction
A particularly powerful aspect of miRNA function is the ability 
of individual miRNAs to regulate a multitude of mRNAs cod­
ing for proteins with related cellular functions. Therefore, we 
explored the possibility that miR­137 has putative target genes 
with similar neuronal functions. Mature miR­137 is highly con­
served across mammals, having exactly the same nucleotide se­
quence in humans, mice and rats. We used  DIANA­microT 3.0, 
a computational algorithm for miRNA target prediction (www 
.microrna.gr/microT), to generate a list of putative human and 
mouse miR­137 targets (i.e., hsa­miR­137, mmu­miR­137). The 
DIANA­micro T 3.0 algorithm is based on several parameters 
calculated individually for each miRNA, and, as opposed to 
other commonly used miRNA prediction tools that use only 
conserved miRNA recognition/binding sites (e.g., TargetScan), 
this algorithm combines both conserved and nonconserved 
miRNA binding sites into a final prediction score, which correl­
ates with the signal to noise ratio (SNR) and hence provides an 
indication of the false­positive rate of the prediction.26,27 The 
higher the prediction score, the lower the amount of false posi­
tives, and as a broad estimate, prediction scores of 19, 7.3 and 5 
correspond to SNRs of 3, 2 and 1.5 and false­positive rates of 
33%, 50% and 66%, respectively.26 In this respect, the DIANA 
algorithm is the only currently available miRNA target predic­
tion tool that also allows for a statistical prediction of the extent 
to which a predicted target is a true target. Hence, to obtain a 
list of predicted human and mouse miR­137 targets with a pre­
dicted false­positive rate of 50% at the most, we used a thresh­
old of at least 7.3 for the prediction score.
Functional classification of predicted human and mouse 
miR-137 targets
To detect significantly enriched gene categories in the pre­
dicted miR­137 target genes/mRNAs, we used the Ingenuity 
Pathway Analysis software package (www.ingenuity.com). It 
uses the Ingenuity Knowledge Base, which is based on infor­
mation from published literature and many other sources, in­
cluding gene expression and gene annotation databases, to as­
sign genes to different groups and categories of functionally 
related genes. Each of these categories can be further divided 
into subcat egories. Ingenuity calculates single p values for the 
enrichment of each gene category using the right­tailed Fisher 
exact test and taking into consideration both the total number 
of molecules from the analyzed data set and the total number 
of molecules linked to the same gene category according to the 
Ingenuity Knowledge Base. Furthermore, for each gene cat­
egory, a multiple testing corrected p value of enrichment, cal­
culated using the Benjamini–Hochberg correction, is provided.
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Measurement of miR-137 levels in a rat model of neuronal 
plasticity
Our initial studies have shown significant enrichment of 
miR­137 in synaptic compartments of the mouse brain.22 To 
further examine the significance of this finding and assess if 
miR­137 levels are altered by synaptic/neuronal plasticity, 
we used a widely accepted in vivo model, the rat barrel cor­
tex,28 to study experience­dependent changes in miR­137 ex­
pression. In the barrel cortex, plasticity can be induced by 
modifying somatosensory input through simple manipula­
tions, such as exposing the animals to an enriched environ­
ment (EE), thus overstimulating the whisker­to­barrel path­
way.29 We used RNA samples from a previous study, 
derived from primary somatosensory (barrel) cortical sam­
ples from adult rats that had been placed into an EE to elicit 
cortical plasticity (see Vallès and colleagues30 for details). 
Precursor (pre­) and mature (mat­) miR­137 expression lev­
els in barrel cortex were determined by quantitative poly­
merase chain reaction (qPCR) immediately following the EE 
session and compared with levels measured in control rats. 
Significant differences in miR­137 expression between EE 
and control rats were determined with a Student t test at a 
significance level of p < 0.05 using SPSS software version 
17.0 (SPSS Inc.).
Identification of putative rat miR-137 targets involved in 
neuronal plasticity
We analyzed a list of putative miR­137 targets involved in neur­
onal plasticity by comparing the putative list of human and 
mouse targets with the list of mRNAs that we previously found 
to be regulated in our rat neuronal plasticity model. This list of 
mRNAs regulated in rat barrel cortex after EE (170 mRNAs up­
regulated and 31 mRNAs downregulated) was obtained using 
microarray analysis (significance analysis of microarrays q ≤ 0.05 
and fold change ≥ |1.25|) in our previous study.30 As opposed 
to human and mouse miRNAs, the  DIANA­microT 3.0 algo­
rithm is not available for rat miRNAs. Therefore, in order to esti­
mate which of the putative human and mouse miR­137 targets 
are also predicted to be rat miR­137 targets, we subsequently 
searched the miRWalk database31 for the “combined prediction 
score” of all putative miR­137 targets that achieved a DIANA 
miR­137 prediction score of at least 7.3 in humans and/or mice. 
This combined prediction score ranges from 1 to 4 and is com­
posed of the individual prediction scores — 0 if the target is not 
predicted and 1 if the target is predicted — from the 4 currently 
available rat microRNA target prediction tools (i.e., miRanda, 
miRDB, TargetScan and miRWalk itself; www .umm.uni ­
heidelberg.de/apps/zmf/mirwalk).
Regulation of neuronal plasticity–involved targets  
by miR-137 in rat cortical neurons
To determine whether the observed experience­dependent 
changes in the expression of the putative miR­137 targets are 
mediated, at least in part, by miR­137, we transfected sequence ­
specific anti­miR­137 and nontargeting anti­miR control (NT) 
into rat primary cortical neurons. Twenty­four hours after 
transfection, expression levels of all EE­regulated mRNAs that 
are also putative miR­137 targets were analyzed by qPCR in 
neurons transfected with anti­miR­137 or NT. The effects of 
anti­miR137 treatment on mature miR­137 levels were also as­
sessed in a comparable parallel experiment. Significant differ­
ences in expression between neurons transfected with anti­
miR­137 and NT were analyzed with a Student t test at a 
significance level of p < 0.05 using SPSS software version 17.0. 
To correct p values for multiple testing32 and to protect against 
type 1 error, p values with a false discovery rate (FDR) of 0.05 
were calculated using an Excel macro.33
Generation of molecular network of neuronal plasticity 
genes regulated by miR-137
We generated a molecular network by integrating the results 
of the bioinformatics analyses with systematic literature 
searches for the function of the neuronal plasticity targets 
whose expression was putatively regulated by miR­137 in rat 
cortical neurons. This was achieved through the molecular 
network building approach that we have previously applied 
to study the molecular basis of various neurodevelopmental 
disorders, including attention­deficit/hyperactivity disorder34 
and autism spectrum disorders (ASDs).35
Results
Human and mouse miR-137 target prediction and 
 functional classification of predicted targets
As described in the Methods section, using DIANA­micro T 3.0. 
with a cut­off of 7.3, we obtained a list of 1049 predicted human 
miR­137 targets and 814 predicted mouse miR­137 targets. The 
Ingenuity tool was subsequently used to identify significantly 
enriched gene categories within the predicted miR­137 targets. 
Table 1 lists the 10 most significantly enriched biological func­
tions and canonical pathways within the predicted human and 
mouse miR­137 targets. In both species, several of the identified 
enriched gene categories are essential for (normal) neuronal de­
velopment and function, including neuritogenesis, action poten­
tial of neurons and ephrin receptor signalling within the pre­
dicted human miR­137 targets and neuro transmission, action 
potential of neurons, ephrin receptor signalling and axonal 
guidance signalling within the predicted mouse miR­137 tar­
gets. These results are in accordance with those from a recent 
study by Wright and colleagues36 in which bioinformatics analy­
ses were conducted on all human miR­137 targets predicted by 
the TargetScan tool. However, the criteria they used to designate 
a gene/mRNA as a putative human miR­137 target were much 
less stringent than the DIANA cut­off that we used in that they 
did not consider any statistical or other cut­off but included all 
genes/mRNAs that contained at least 1 conserved seed­binding 
site for human miR­137 in their subsequent bioinformatics an­
alyses, as revealed by the TargetScan target predictions website. 
This approach suggests that a (much) larger proportion of genes 
serving as a starting point for analyses in the study by Wright 
and colleagues36 than our study may have been false positives.
Vallès et al.
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Regulation of miR-137 expression and putative miR-137 
targets in the rat barrel cortex following EE
We detected significantly reduced levels of pre­miR­137 (~66% 
reduction; t test, p = 0.006) and mat­miR­137 (~50% reduction; t 
test, p = 0.034) in the barrel cortex of rats exposed to EE com­
pared with pre­ and mat­miR­137 levels in the barrel cortex of 
control animals (Fig. 1A). Through applying the prediction criter ia 
for human, mouse and rat miR­137 targets (see the Methods sec­
tion), we identified 14 putative miR­137 target mRNAs that we 
previously found to be regulated among the transcriptomes ex­
amined in a rat neuronal plasti city model following EE30 (Table 2). 
The fact that all these predicted targets were upregulated in 
their mRNA levels is in keeping with the present finding that 
miR­137 expression was downregulated following EE.
Effect of endogenous miR-137 silencing on the expression 
of EE-regulated putative miR-137 targets
To examine the influence of miR­137 on the expression of the 
putative miR­137 targets identified in the EE neuronal plasti city 
model, we have repressed endogenous miR­137 function in pri­
mary cortical neurons in vitro using a sequence­specific anti­
miR­137 inhibitor. This inhibitor significantly reduces miR­137 
levels (see the Appendix, Fig. S1). After miR­137 decrease, we 
found a significant increase in the levels of 5 out of the 14 (36%) 
predicted and tested mRNA targets, namely Egr2, Dusp1, Ptgs2, 
Dusp4 and Sgk1 (t test followed by FDR multiple testing correc­
tion; all p < 0.05, corrected; Fig. 1B). Klf4, Crem, Klf2, and Obfc2a 
levels increased to a lesser and borderline significant extent (t 
test followed by FDR multiple testing correction, all p < 0.10), 
while the mRNA levels of Med14, Spty2d1, Irs2 and Usp38 re­
mained unchanged. The finding that Dio2 mRNA levels were 
significantly decreased in neurons transfected with anti­miR­137 
(t test followed by FDR multiple testing correction; p < 0.05, cor­
rected) may be due to additional posttranscriptional regulatory 
mechanisms potentially exerting secondary signalling effects. 
These results suggest that miR­137, at least partially, modulates 
the expression of a significant number of genes in the rat barrel 
cortex upon induction of neuronal plasticity by EE.
Generation of molecular network of neuronal plasticity 
genes regulated by miR-137
Bioinformatics analyses of the 5 putative miR­137 targets up­
regulated in both the EE neuronal plasticity model and follow­
ing loss­of function of endogenous miR­137 in vitro showed that 
some of the most significantly enriched functional gene cat­
egories are directly related to the normal development and/or 
function of the nervous system (i.e., the biological functions epi­
leptic seizure, behaviour and spatial memory; Table 3). In addi­
tion, 2 of the 6 significantly enriched canonical pathways (gluco­
corticoid receptor signalling and aldosterone signalling in 
epithelial cells) point toward a role for these miR­137 targets in 
corticosteroid­related signalling. Furthermore, glucocorticoid re­
ceptor signalling — the most significantly enriched canonical 
pathway within the 5 targets — and protein kinase A signalling 
are the only 2 pathways that were significantly enriched in all 3 
Table 1: Enrichment analyses of the genes/mRNAs predicted to be 
targets of human and mouse miR-137 using the DIANA tool*
Functional gene category p value†
No. of 
genes
Human miR-137 putative targets
Biological functions
Cancer < 0.001 531
Organismal death < 0.001 238
Size of body < 0.001 98
Movement disorders < 0.001 117
Locomotion < 0.001 45
Neuritogenesis < 0.001 58
Learning < 0.001 51
Epilepsy < 0.001 40
Action potential of neurons < 0.001 22
Chorea < 0.001 72
Canonical pathways
PAK signalling 0.002 16
Protein kinase A signalling 0.003 39
Ephrin receptor signalling 0.006 22
Paxillin signalling 0.008 15
Agrin Interactions at neuromuscular junction 0.008 12
Cardiac β-adrenergic signalling 0.009 18
D-myo-inositol-5-phosphate metabolism 0.009 18
SAPK/JNK signalling 0.009 14
Glucocorticoid receptor signalling 0.009 27
Sertoli cell-sertoli cell junction signalling 0.009 21
Mouse miR-137 putative targets
Biological functions
Organismal death < 0.001 200
Cancer < 0.001 410
Size of body < 0.001 84
Development of muscle < 0.001 43
Neurotransmission < 0.001 46
Development of digestive system < 0.001 39
Locomotion < 0.001 37
Action potential of neurons < 0.001 19
Morphogenesis of embryonic limb < 0.001 15
Morphogenesis of forelimb < 0.001 9
Canonical pathways
Paxillin signalling < 0.001 17
PAK signalling < 0.001 16
Agrin Interactions at neuromuscular junction < 0.001 12
Ephrin receptor signalling 0.003 18
Axonal guidance signalling 0.003 34
Glucocorticoid receptor signalling 0.004 24
Ephrin A signalling 0.004 9
Rac signalling 0.006 13
Protein kinase A signalling 0.006 30
Sertoli cell-sertoli cell junction signalling 0.006 18
JNK = jun amino-terminal kinases; PAK = p21-activated kinases; SAPK = stress-
activated protein kinases.  
*The top 10 enriched gene categories for biological functions and canonical pathways (from 
the Ingenuity tool, www.ingenuity.com) are shown (see Methods). All categories that are 
directly related to the (normal) development and/or function of the nervous system are 
underlined. 
†Significance was determined from a single test p value calculated using the right-tailed 
Fisher exact test and taking into consideration both the total number of molecules from the 
analyzed data set and the total number of molecules linked to the same gene category 
according to the Ingenuity Knowledge Base. Adjusted significance was determined from 
multiple test–corrected p values using the Benjamini-Hochberg correction (only categories 
reaching a corrected statistical significance of p < 0.05 are shown).
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gene  enrichment analyses that we conducted (i.e., the analyses 
of the predicted human and mouse miR­137 targets and of the 
5 putative miR­137 targets that were upregulated following the 
antagomir mediated loss of function of miR­137 levels in pri­
mary neurons in vitro; Tables 1 and 3).
By integrating the results of the bioinformatics analyses with 
systematic literature searches for the functions of the proteins 
encoded by the 5 confirmed miR­137 target mRNAs, we built a 
molecular network that contains putative neuronal plasticity–
related miR­137 targets (i.e., COX2 [encoded by PTGS2], 
DUSP1, DUSP4, EGR2, SGK1) and that may be involved in 
regulating neuronal plasticity through modulating glucocorti­
coid receptor–dependent signalling (Fig. 2). This outcome pro­
vides a testable model that requires further confirmation in 
follow­ up studies. In addition to the 5 miR­137 targets, we 
placed the proteins encoded by 3 known miR­137 targets that 
have previously yielded genome­wide significant association 
with schizophrenia (i.e., CACNA1C, TCF4 and ZNF804A),37,38 
as well as 5 neuronal plasticity–related proteins that function­
ally link the other network components (i.e., BDNF, DDIT3, 
EGR1, the glucocorticoid receptor itself and GRIN1) in the gen­
erated network (Fig. 2). Interestingly, the DIANA tool revealed 
Fig. 1: (A) Expression levels of microRNA-137 (miR-137) in the barrel cortex upon exposure of the rats to environmental enrichment (EE). We used 
a quantitative polymerase chain reaction (qPCR) assay to assess levels of both precursor (pre-) and mature (mat-) miR-137 in total RNA samples 
from the barrel cortex of rats exposed to EE and control animals. Levels of pre- and mat-miR-137 are expressed relative to U6 small nuclear RNA, 
used as an internal control; the scale of relative expression is ×10−5. Error bars represent the standard error of the mean (SEM) for control (n = 6) and 
EE (n = 12) measurements. Results are from 2 and 4 independent pooled samples (n = 2–3 animals per pool), respectively, assessed in triplicate us-
ing unpaired 2-tailed Student t tests (*p < 0.05, **p < 0.01). (B) Expression levels of the putative miR-137 target messenger RNAs (mRNAs) in a 
miRNA loss of function experiment. Primary rat cortical neurons were transfected with anti-miR-137 or, as a control, nontargeting short oligo-
nucleotides (NT). Expression levels of predicted miR-137 target mRNAs were quantified by qPCR analysis 24 hours after oligonucleotide transfec-
tion. The putative miR-137 target mRNAs were previously found to be associated with activity-dependent plasticity in the rat barrel cortex.30 Error 
bars represent the SEM for independ ent experiments (n = 4); unpaired 2-tailed Student t test followed by Benjamini–Hochberg false discovery rate 
(FDR) multiple testing correction,32 #p < 0.10, FDR-corrected; *p < 0.05, FDR-corrected; **p < 0.01, FDR-corrected; ***p < 0.001, FDR-corrected.
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Table 2: Fourteen putative miR-137 target genes upregulated by enriched environment in the rat barrel cortex
Gene* Gene description
Microarray analysis DIANA scores miRWalk score
Fold change SAM q value hsa-miR-137 mmu-miR-137 rno-miR-137
Egr2† Early growth response 2 3.73 < 0.001 25.71 25.28 4
Dusp1† Dual specificity phosphatase 1 3.26 < 0.001 11.63 12.15 2
Klf4 Kruppel-like factor 4 (gut) 1.77 < 0.001 12.93 15.10 3
Ptgs2† Prostaglandin-endoperoxide synthase 2 1.61 < 0.001 7.90 — —
Dio2 Deiodinase. iodothyronine. type II 1.56 < 0.001 — 8.11 1
Crem cAMP responsive element modulator 1.51 < 0.001 9.02 10.19 1
Klf2 Kruppel-like factor 2 (lung) 1.42 < 0.001 7.72 10.19 —
Med14 Mediator complex subunit 14 1.41 < 0.001 24.66 24.06 —
Spty2d1 SPT2. Suppressor of Ty. domain containing 1 (S. cerevisiae) 1.38 < 0.001 22.44 19.49 —
Irs2 Insulin receptor substrate 2 1.36 < 0.001 12.93 — —
Dusp4† Dual specificity phosphatase 4 1.35 0.001 28.31 17.14 —
Usp38 Ubiquitin specific peptidase 38 1.31 < 0.001 10.33 — —
Obfc2a Oligonucleotide/oligosaccharide-binding fold containing 2A 1.29 < 0.001 22.19 — —
Sgk1† Serum/glucocorticoid regulated kinase 1 1.29 < 0.001 12.93 13.14 3
DIANA = DNA intelligent analysis; SAM = significance analysis of microarrays. 
*For each gene, the fold change and SAM q value from our previous study of environmental enrichment–induced mRNA expression changes are shown.30  
†Regulated after miR–137 inhibition in vitro (as shown in Fig. 1B).
Vallès et al.
6 J Psychiatry Neurosci
that the glucocorticoid receptor (encoded by NR3C1) is a pre­
dicted target of both human miR­ 137 (prediction score: 7.72) 
and mouse miR­137 (prediction score: 18.41).
The network is described in detail in the Appendix, and the 
current knowledge about the functions of the individual net­
work proteins is delineated. Remarkably, except for DDIT3, all 
proteins in the network have been implicated in the etiology of 
schizophrenia through genetic evidence and/or mRNA/protein 
expression data (see the Appendix, Table S1), which provides a 
further functional and molecular link between miR­137­ 
dependent dysregulation and schizophrenia.
Discussion
One of the main cognitive deficits observed in patients with 
schizophrenia is altered perception, resulting in hallucinations 
and delusions.39 While visual and auditory perception deficits 
in these patients have been well described, recent studies sug­
gest that deficits in all the other sensory systems (olfactory, gus­
tative, somatosensory) are also associated with schizophrenia 
pathology.40 Interestingly, sensory training improves cognitive 
abilities in patients with schizophrenia and results in changes 
of peripheral biomarker levels of neuronal plasticity.41 Accord­
ingly, sensory stimulation through EE counteracted behaviours 
related to schizophrenia (e.g., stereotypical behaviour, impaired 
prepulse inhibition) in a mouse model of the disorder.42 Since 
the somatosensory system is the dominant sensory system in 
rodents, with a clear somatotopic representation of the whis­
kers (the main somatosensory organs) in the primary somato­
sensory cortex, we chose it to study the molecular basis of al­
tered perception induced by sensory training in rodents.28
In the present study, we used bioinformatics and literature 
analyses to generate a molecular network of potentially inter­
acting miR­137 targets during the induction of plasticity in the 
rat barrel cortex. We also identified 5 putative miR­137 target 
mRNAs by combining transcriptomics data derived from the 
rat neuronal plasticity model of somatosensory experience with 
the results of loss of miR­137 function in rat primary cortical 
neurons. The downregulation of miR­137 following EE that we 
observed is in keeping with other findings demonstrating that 
miRNA levels can be modulated upon the induction of long­
term synaptic plasticity43 (e.g., for miR­13244 and for miR­485 
during homeostatic plasticity45). Furthermore, a number of 
miRNAs are capable of fine­tuning the expression of synaptic 
plasticity proteins involved in actin cytoskeleton dynamics, or 
mRNA transport, resulting in spine morphogenesis.46–48
The molecular network that we have constructed includes 
the proteins encoded by the 5 miR­137 target mRNAs found 
to be upregulated in the rat barrel cortex following EE, as well 
as 3 previously validated miR­137 target proteins. Notably, all 
but 1 protein (DDIT3) within this network have been linked to 
schizophrenia through direct genetic evidence and/or expres­
sion data. Moreover, the proposed miR­137­regulated net­
work is involved in experience­dependent neuronal plasticity 
through modulating glucocorticoid receptor–dependent sig­
nalling, a pathway that recently has been functionally linked 
to synaptic/neuronal plasticity49–52 and directly associated 
with schizophrenia.53,54 The glucocorticoid receptor pathway 
has been shown previously to be regulated both in a direct 
and indirect fashion by miR­124a and miR­18,55 whereas our 
results suggests that this pathway, at least partially, is regu­
lated through miR­137. Furthermore, combined with the 
aforementioned findings from other groups, our results sug­
gest a direct functional link between impaired miR­137­ 
dependent regulation and schizophrenia through glucocorti­
coid receptor signalling.
Interestingly, although less strongly, miR­137 has been gen­
etically linked to a number of other brain disorders, namely Al­
zheimer disease56 and 2 neurodevelopmental disorders other 
than schizophrenia, intellectual disability22 and ASDs.57 Nota­
bly, all these disorders are genetically and functionally associ­
ated with dysregulated stress and hypothalamic–pituitary– 
adrenal axis responses, which may involve, among other 
pathways, altered glucocorticoid receptor signalling50,58–61 and 
impaired synaptic plasticity.62–65 This suggests that dysregula­
tion of miR­137 — and possibly impaired glucocorticoid recep­
tor signalling — may lead to impaired synaptic plasticity, rep­
resenting a common mechanism underlying cognitive deficits 
associated with clinically distinct neurologic disorders.
Table 3: Bioinformatics-based enrichment analyses of the 
5 predicted miR-137 target genes that are upregulated following 
enriched environment in the rat barrel cortex (Dusp1, Dusp4, Egr2, 
Ptgs2 and Sgk1)*
Functional gene category Genes p value‡
Biological functions
Epileptic seizure† Dusp1, Egr2, Ptgs2 0.002
Glomerular filtration rate of 
kidney
Ptgs2, Sgk1 0.002
Weight loss Dusp1, Ptgs2, Sgk1 0.002
Behaviour† Dusp1, Egr2, Ptgs2, 
Sgk1
0.003
Hyperalgesia Ptgs2, Sgk1 0.003
Failure of kidney Dusp1, Ptgs2 0.003
Damage of bone Dusp1, Ptgs2 0.003
Blood pressure Dusp1, Ptgs2, Sgk1 0.003
Albuminuria Ptgs2, Sgk1 0.003
Spatial memory† Ptgs2, Sgk1 0.003
Canonical pathways
Glucocorticoid receptor 
signalling
Dusp1, Ptgs2, Sgk1 0.001
Protein kinase A signalling Dusp1, Dusp4, Ptgs2 0.002
Aldosterone signalling in 
epithelial cells
Dusp1, Sgk1 0.010
ERK/MAPK signalling Dusp1, Dusp4 0.011
cAMP-mediated signalling Dusp1, Dusp4 0.012
cAMP = adenosine 3′,5′-cyclic monophosphate; ERK = extracellular signal-regulated 
kinases; MAPK = mitogen-activated protein kinases.  
*The top 10 enriched gene categories for “biological functions” and all significantly 
enriched categories for “canonical pathways” (from the Ingenuity tool, www.ingenuity.
com) are shown (see Methods).  
†Categories that are directly related to the (normal) development and/or function of the 
nervous system. 
‡Significance was determined from a single test p value calculated using the right-
tailed Fisher exact test and taking into consideration both the total number of 
molecules from the analyzed data set and the total number of molecules linked to the 
same gene category according to the Ingenuity Knowledge Base. Adjusted 
significance was determined from multiple test–corrected p values using the 
Benjamini–Hochberg correction (only categories reaching a corrected statistical 
significance of p < 0.05 are shown).
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Finally, our finding that EE­mediated sensory experience 
caused a significant downregulation of miR­137 expression in 
the rat barrel cortex, along with the finding that EE counter­
acts schizophrenia­relevant behaviours in a mouse schizo­
phrenia model (e.g., stereotypical behaviour, impaired pre­
pulse inhibition),42 suggests that reducing brain miR­137 
levels may lower the risk for schizophrenia­related behaviour. 
In this respect, it is of interest to note that in the human pre­
frontal cortex miR­137 levels significantly decrease with age, 
with the most prominent decline in expression being ob­
served in or just after late adolescence,66 which is the window 
of onset for schizophrenia. This notion indicates that insufficient 
Fig. 2: A microRNA-137 (miR-137)–regulated protein network that is implicated in neuronal plasticity through modulating glucocorticoid 
receptor– dependent signalling. The 5 novel miR-137 targets from this study (DUSP1; DUSP4; EGR2; PTGS2, which encodes the COX2 pro-
tein; and SGK1), as well as 3 previously validated miR-137 targets encoded by genes with a genome-wide significant association with schizo-
phrenia (CACNA1C, TCF4 and ZNF804A), are depicted in yellow. The glucocorticoid receptor (GR; shown in blue) protein (encoded by 
NR3C1) is a predicted target of miR-137 in humans (DIANA prediction score: 7.72) and mice (DIANA prediction score: 18.41). Furthermore, all 
proteins with a red border have been implicated in schizophrenia through direct genetic evidence and/or messenger RNA/protein expression 
data (see the Appendix, Table S1). The network is described in full detail in the Appendix, and the current knowledge about the functions of 
the network proteins is presented. 
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decline in miR­137 during adolescence may contribute to the 
pathoetiology of schizophrenia. In support of this hypothesis, 
a recent study found that the schizophrenia risk allele of 
rs1625579 (the miR­137­linked SNP) is significantly associated 
with a lower miR­137 expression level in postmortem prefron­
tal cortex tissue of the control group but not the schizophrenia 
group.67 Importantly, beneficial effects of EE have also been 
reported in rodent models of Alzheimer disease,68,69 intellec­
tual disability70 and ASDs,71,72 raising the intriguing possibility 
that modulating miR­137 levels may result in altered pheno­
types of these 3 miR­137­linked neurologic disorders.22,56,57
Limitations
We used the DIANA algorithm to generate a list of predicted 
human and mouse miR­137 targets. Although the algorithm is 
one of the best currently available tools to predict miRNA tar­
gets26,27 it does not predict miRNA targets in rats, our animal 
model of choice to study the expression of miR­137 and its pre­
dicted targets in the context of neuronal plasticity. Hence, to esti­
mate which of the putative human and mouse miR­137 targets 
are also predicted to be targets in rats, we used the miRWalk 
data base to obtain a combined prediction score using the 4 cur­
rently available tools that predict targets of rat miRNA. This 
score indicated that 2 of the 5 predicted miR­137 targets regu­
lated by neuronal plasticity and upregulated after loss of miR­
137 function experiments, Ptgs2 and Dusp4, are not predicted 
targets in rats, which implies that the upregulation of these tar­
gets may be due to indirect effects. Therefore, follow­up studies 
should be performed to assess whether these 2 predicted targets 
are indeed direct miR­137 targets in the rat. In line with this, 
gain of miR­137 function experiments may also add relevant in­
formation. Although these points should be taken into consider­
ation, our findings are very much in keeping with those of other 
studies and strongly support the important role of miR­137 in 
neuronal plasticity and the etiology of schizophrenia.
Conclusion
The outcomes of our studies suggest a critical role of miR­137 
in modulating experience­dependent cortical plasticity via a 
glucocorticoid receptor signalling pathway. As such, the data 
provide a scope for developing novel molecular therapies 
aimed at lowering brain levels of miR­137 in order to treat 
schizophrenia and other miR­137­linked disorders.
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